BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; a… Read more
BioNexus Gene Lab Corp Common stock (BGLC) - Net Assets
Latest net assets as of September 2025: $6.82 Million USD
Based on the latest financial reports, BioNexus Gene Lab Corp Common stock (BGLC) has net assets worth $6.82 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.62 Million) and total liabilities ($804.97K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.82 Million |
| % of Total Assets | 89.44% |
| Annual Growth Rate | N/A |
| 5-Year Change | 24.93% |
| 10-Year Change | N/A |
| Growth Volatility | 527.28 |
BioNexus Gene Lab Corp Common stock - Net Assets Trend (2016–2024)
This chart illustrates how BioNexus Gene Lab Corp Common stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioNexus Gene Lab Corp Common stock (2016–2024)
The table below shows the annual net assets of BioNexus Gene Lab Corp Common stock from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $8.32 Million | -13.82% |
| 2023-12-31 | $9.66 Million | +44.90% |
| 2022-12-31 | $6.67 Million | -7.17% |
| 2021-12-31 | $7.18 Million | +7.77% |
| 2020-12-31 | $6.66 Million | +493.58% |
| 2019-12-31 | $1.12 Million | -26.25% |
| 2018-12-31 | $1.52 Million | +1508.36% |
| 2017-12-31 | $94.63K | +7317.85% |
| 2016-12-31 | $-1.31K | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioNexus Gene Lab Corp Common stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 344118200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $17.33 Million | 208.25% |
| Other Comprehensive Income | $-555.00K | -6.67% |
| Total Equity | $8.32 Million | 100.00% |
BioNexus Gene Lab Corp Common stock Competitors by Market Cap
The table below lists competitors of BioNexus Gene Lab Corp Common stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PT Dewi Shri Farmindo Tbk
JK:DEWI
|
$3.28 Million |
|
Truong Long Engineering and Auto JSC
VN:HTL
|
$3.29 Million |
|
SEI
BK:SEI
|
$3.29 Million |
|
Absolicon Solar Collector AB Series B
ST:ABSL-B
|
$3.29 Million |
|
Carmat
PA:ALCAR
|
$3.28 Million |
|
TEMPUS RESOURCES LTD
F:4W0
|
$3.28 Million |
|
Hiper Global Ltd
TA:HIPR
|
$3.28 Million |
|
Tissue Repair Ltd
AU:TRP
|
$3.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioNexus Gene Lab Corp Common stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,657,852 to 8,322,804, a change of -1,335,048 (-13.8%).
- Net loss of 1,598,342 reduced equity.
- Dividend payments of 68,130 reduced retained earnings.
- Other comprehensive income increased equity by 122,294.
- Other factors increased equity by 209,130.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.60 Million | -19.2% |
| Dividends Paid | $68.13K | -0.82% |
| Other Comprehensive Income | $122.29K | +1.47% |
| Other Changes | $209.13K | +2.51% |
| Total Change | $- | -13.82% |
Book Value vs Market Value Analysis
This analysis compares BioNexus Gene Lab Corp Common stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.54x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $0.00 | $2.54 | x |
| 2017-12-31 | $0.15 | $2.54 | x |
| 2018-12-31 | $2.75 | $2.54 | x |
| 2019-12-31 | $1.56 | $2.54 | x |
| 2020-12-31 | $7.77 | $2.54 | x |
| 2021-12-31 | $5.03 | $2.54 | x |
| 2022-12-31 | $4.63 | $2.54 | x |
| 2023-12-31 | $5.61 | $2.54 | x |
| 2024-12-31 | $4.67 | $2.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioNexus Gene Lab Corp Common stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16.81%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 1.25x
- Recent ROE (-19.20%) is above the historical average (-19.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-703.90 |
| 2017 | -130.78% | -114.92% | 0.08x | 13.45x | $-133.21K |
| 2018 | 1.74% | 12.46% | 0.13x | 1.09x | $-125.74K |
| 2019 | -21.96% | -194.14% | 0.10x | 1.10x | $-358.71K |
| 2020 | 16.42% | 9.61% | 1.13x | 1.52x | $427.88K |
| 2021 | 10.47% | 5.62% | 1.40x | 1.33x | $33.59K |
| 2022 | -5.34% | -3.26% | 1.25x | 1.31x | $-1.02 Million |
| 2023 | -27.22% | -26.91% | 0.86x | 1.18x | $-3.59 Million |
| 2024 | -19.20% | -16.81% | 0.91x | 1.25x | $-2.43 Million |
Industry Comparison
This section compares BioNexus Gene Lab Corp Common stock's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $7,181,833,981
- Average return on equity (ROE) among peers: 7.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioNexus Gene Lab Corp Common stock (BGLC) | $6.82 Million | 0.00% | 0.12x | $3.28 Million |
| AirBoss of America Corp (ABSSF) | $197.00 Million | -16.19% | 1.24x | $57.06 Million |
| Asia Carbon Industries Inc (ACRB) | $19.13 Million | 17.11% | 0.33x | $0.98 |
| Aimia Inc (AIMFF) | $1.29 Billion | -4.63% | 2.83x | $103.68 Million |
| L'Air Liquide S.A (AIQUF) | $11.83 Billion | 14.08% | 1.26x | $107.70 Billion |
| Akzo Nobel N.V (AKZOF) | $7.58 Billion | 14.03% | 1.29x | $9.73 Billion |
| Albemarle Corp (ALB) | $545.00 Million | 9.41% | 1.09x | $19.53 Billion |
| ALPEK S.A.B. de C.V (ALPKF) | $49.59 Billion | 15.64% | 1.50x | $214.40 Million |
| Altech Batteries Limited (ALTHF) | $97.54 Million | -5.87% | 0.01x | $27.89 Million |
| Arcadium Lithium plc (ALTM) | $333.00 Million | 14.14% | 0.12x | $6.26 Billion |
| Alto Ingredients Inc (ALTO) | $345.21 Million | 13.35% | 0.40x | $212.84 Million |